Quizartinib (AC220)

For research use only. Not for use in humans.

目录号：S1526 中文名称：奎扎替尼

CAS No. 950769-58-1

Quizartinib (AC220)是一种二代FLT3抑制剂，作用于Flt3(ITD/WT)，在MV4-11和 RS4;11细胞中IC50分别为1.1 nM/4.2 nM，作用于Flt3比作用于KIT，PDGFRA，PDGFRB，RET，和CSF-1R选择性高10倍。Quizartinib (AC220)可诱导肿瘤细胞的凋亡。Phase 3。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 2891.02	现货
5mg	RMB 1729.76	现货
50mg	RMB 7933.51	现货
200mg	RMB 20229.3	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Quizartinib (AC220)发表文献104篇：

Cancer Cell, 2018, 34(2):315-330

PubMed: 30033091 ( click the link to review the publication )

Nat Med, 2017, 23(1):69-78

PubMed: 27941792 ( click the link to review the publication )

Oncol Lett, 2022, 23(2):51

PubMed: 34992684 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(21)00507-4

PubMed: 34289383 ( click the link to review the publication )

Clin Cancer Res, 2021, 10.1158/1078-0432.CCR-20-3458

PubMed: 34103301 ( click the link to review the publication )

Autophagy, 2021, 1-10

PubMed: 33446043 ( click the link to review the publication )

Leukemia, 2021, 10.1038/s41375-021-01308-z

PubMed: 34127794 ( click the link to review the publication )

Leukemia, 2021, 10.1038/s41375-021-01490-0

PubMed: 34903841 ( click the link to review the publication )

Cancer Res, 2021, canres.0955.2021

PubMed: 34551960 ( click the link to review the publication )

Cancer Res, 2021, canres.3761.2020

PubMed: 34215619 ( click the link to review the publication )

Blood Cancer J, 2021, 11(3):57

PubMed: 33714981 ( click the link to review the publication )

Protein Cell, 2021, 10.1007/s13238-021-00858-3

PubMed: 34291435 ( click the link to review the publication )

Cancers (Basel), 2021, 13(14)3464

PubMed: 34298678 ( click the link to review the publication )

Cell Death Discov, 2021, 7(1):121

PubMed: 34035227 ( click the link to review the publication )

Cell Chem Biol, 2021, S2451-9456(21)00475-X

PubMed: 34762849 ( click the link to review the publication )

Front Immunol, 2021, 12:699128

PubMed: 34249005 ( click the link to review the publication )

Cancer Discov, 2021, candisc.0738.2020

PubMed: 33436370 ( click the link to review the publication )

Mol Cancer Ther, 2021, 20(4):676-690

PubMed: 33568357 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:662868

PubMed: 34589478 ( click the link to review the publication )

mSphere, 2021, 6(1)e00986-20

PubMed: 33408225 ( click the link to review the publication )

J Cell Mol Med, 2021, 25(24):11039-11052

PubMed: 34791807 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Cell Signal, 2021, 87:110144

PubMed: 34509612 ( click the link to review the publication )

Chem Biol Drug Des, 2021, 10.1111/cbdd.13992

PubMed: 34877799 ( click the link to review the publication )
Oncol Lett, 2021, 21(5):397

PubMed: 33777220 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00639-4

PubMed: 34731453 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Thorac Cancer, 2021, 10.1111/1759-7714.13849

PubMed: 33566442 ( click the link to review the publication )

Cell Rep, 2020, 33(1):108221

PubMed: 33027668 ( click the link to review the publication )

Haematologica, 2020, 15 pii: haematol 2019 244020

PubMed: 32414851 ( click the link to review the publication )

Mol Cell Proteomics, 2020, 10.1074/mcp.RA119.001504

PubMed: 32102969 ( click the link to review the publication )

Eur J Med Chem, 2020, 193:112232

PubMed: 32199135 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(3):2308-2318

PubMed: 31881122 ( click the link to review the publication )

J Cell Mol Med, 2020, 25

PubMed: 32450611 ( click the link to review the publication )

Sci Rep, 2020, 10(1):16187

PubMed: 32999332 ( click the link to review the publication )

Sci Rep, 2020, 10(1):1906

PubMed: 32024878 ( click the link to review the publication )

Transl Oncol, 2020, 1;13(4):100766

PubMed: 32247263 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Pharmacol Res, 2020, 151:104556

PubMed: 31778791 ( click the link to review the publication )

FEBS Open Bio, 2020, 10.1002/2211-5463.12827

PubMed: 32128992 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

Sci Transl Med, 2019,

PubMed: 31484791 ( click the link to review the publication )

Autophagy, 2019, 15(9):1558-1571

PubMed: 30821613 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31554189 ( click the link to review the publication )

Theriogenology, 2019, 126:145-152

PubMed: 30553232 ( click the link to review the publication )

Cell Rep, 2019, 26(11):2916-2928.e13

PubMed: 30865883 ( click the link to review the publication )
FEBS Lett, 2019, 593(16):2162-2176

PubMed: 31135968 ( click the link to review the publication )

Hemasphere, 2019, 3(2):e182

PubMed: 31723821 ( click the link to review the publication )

Oncotarget, 2019, 10(58):6111-6123

PubMed: 31692922 ( click the link to review the publication )

Blood, 2018, 25;131(4):426-438

PubMed: 29187377 ( click the link to review the publication )

Blood, 2018, 132(1):67-77.

PubMed: 29784639 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(7):1716-1726

PubMed: 29330206 ( click the link to review the publication )

Leukemia, 2018, 32(2):313-322

PubMed: 28895560 ( click the link to review the publication )

Haematologica, 2018, haematol.2018.189399

PubMed: 29748445 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(10):2417-2429

PubMed: 29463558 ( click the link to review the publication )

Oncogene, 2018, 37(6):787-797

PubMed: 29059168 ( click the link to review the publication )

mBio, 2018, 9(2)e00682-18

PubMed: 29691342 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):138

PubMed: 29374185 ( click the link to review the publication )

Neoplasia, 2018, 20(1):1-11

PubMed: 29172076 ( click the link to review the publication )

Nephrol Dial Transplant, 2018, 10.1093/ndt/gfy385

PubMed: 30590794 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190682

PubMed: 29298347 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0196805

PubMed: 29723246 ( click the link to review the publication )

Exp Hematol, 2018, 58:52-58

PubMed: 28947392 ( click the link to review the publication )

J Ophthalmol, 2018, 2018:2518568

PubMed: 29854425 ( click the link to review the publication )

Oncotarget, 2018, 9(76):34240-34258

PubMed: 30344940 ( click the link to review the publication )

Leukemia, 2018, 32(11):2374-2387

PubMed: 29743719 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16917-16931

PubMed: 29682194 ( click the link to review the publication )

Blood, 2017, 130(1):48-58

PubMed: 28490572 ( click the link to review the publication )

Leukemia, 2017, 31(11):2336-2346

PubMed: 28280274 ( click the link to review the publication )

Cancer Res, 2017, 77(7):1697-1708

PubMed: 28108507 ( click the link to review the publication )
Leuk Lymphoma, 2017, 10.1080/10428194.2017.1289522

PubMed: 28276286 ( click the link to review the publication )

Blood Adv, 2017, 1(20):1635-1644

PubMed: 29296810 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52026-52044

PubMed: 28881711 ( click the link to review the publication )

Blood, 2016, 127(23):2890-902

PubMed: 27099147 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1528-37

PubMed: 26822154 ( click the link to review the publication )

Cancer Res, 2016, 76(5):1214-24

PubMed: 26833125 ( click the link to review the publication )

Sci Rep, 2016, 6:28032

PubMed: 27346558 ( click the link to review the publication )

Ann Hematol, 2016, 95(5):783-91

PubMed: 26891877 ( click the link to review the publication )

PLoS One, 2016, 11(7):e0158290

PubMed: 27387666 ( click the link to review the publication )

Int J Hematol, 2016, 103(1):95-106

PubMed: 26590920 ( click the link to review the publication )

Oncotarget, 2016, 7(31):49786-49799

PubMed: 27391351 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13886-901

PubMed: 26883104 ( click the link to review the publication )

Leukemia, 2015, 29(12):2382-9

PubMed: 26172401 ( click the link to review the publication )

Leukemia, 2015, 29(12):2390-2

PubMed: 26108694 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Oncotarget, 2015, 6(35):38061-78

PubMed: 26515730 ( click the link to review the publication )

Sci Adv, 2015, 1(8):e1500221

PubMed: 26601252 ( click the link to review the publication )

Blood, 2014, 123(18):2826-37

PubMed: 24668492 ( click the link to review the publication )

Blood, 2014, 123(5):734-42

PubMed: 24282218 ( click the link to review the publication )

Nat Commun, 2014, 5:3672

PubMed: 24739485 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2092-103

PubMed: 24436473 ( click the link to review the publication )

Leukemia, 2014, 28(11):2197-205

PubMed: 24699302 ( click the link to review the publication )

Leukemia, 2014, 28(2):293-301

PubMed: 23748345 ( click the link to review the publication )

Genes Dev, 2014, 28(11):1179-90

PubMed: 24888589 ( click the link to review the publication )
Proc Natl Acad Sci USA, 2014, 10.1073/pnas.1320661111

PubMed: 24623852 ( click the link to review the publication )

Cancer Discov, 2014, 4(2):200-15

PubMed: 24362263 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2315-27

PubMed: 25053825 ( click the link to review the publication )

J Biol Chem, 2014, 289(45):31053-65

PubMed: 25237195 ( click the link to review the publication )

PLoS One, 2013, 8(8): e71266

PubMed: 23967177 ( click the link to review the publication )

PLoS One, 2013, 8(9):e74653

PubMed: 24040307 ( click the link to review the publication )

Leuk Res, 2013, 37(11):1557-64

PubMed: 23998902 ( click the link to review the publication )

Br J Pharmacol, 2012, 166(3):858-76

PubMed: 22250956 ( click the link to review the publication )

产品安全说明书

Target Protein Ligand抑制剂选择性比较

生物活性

产品描述

特性

AC220是二代FLT3抑制剂，且作为临床FLT3抑制剂的第一候选药。

靶点

FLT3 (ITD) ^[1] (MV4-11 cells)	FLT3 (WT) ^[1] (RS4;11 cells)
1.1 nM	4.2 nM

体外研究

AC220是最有效的FLT3选择性抑制剂，可用于治疗急性骨髓性白血病(AML)。AC220在生化和细胞实验中具有低纳摩尔效果和特别的激酶选择性，抑制大部分人类蛋白激酶时具有高选择性。AC220是治疗急性骨髓性白血病(AML)的新型FLT3抑制剂。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
HL60/VCR	MnfUSpVv[3Srb36gRZN{[Xl?	MkHRNE4yNTFyIN88US=>	NHq2Wm0{OCCvaX6=	NVuwe3lN\W6qYX7j[ZMhfXC2YXvlJI9nKHO3YoP0doF1\XNib3[gRWJETzJiYX7kJGFDS0JzIHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{	MoWxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NkexO\|coRjJ\|OU[3NVc4RC:jPh?=
K562/ABCB1	NE[4WWtHfW6ldHnvckBCe3OjeR?=	MmDUNE4yNTFyIN88US=>	NGXLenk{OCCvaX6=	NETDPI9mdmijbnPld{B2eHSja3Wgc4Yhe3Wkc4TyZZRmeyCxZjDBRmNIOiCjbnSgRWJESjFiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ?	NFHmcmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2O\|E4Pyd-MkO5OlcyPzd:L3G+
8226/MR20	M3XIZWZ2dmO2aX;uJGF{e2G7	M4nBXVAvOS1zMDFOwG0>	NXrBUIpuOzBibXnu	M4PVUoVvcGGwY3XzJJVxfGGtZTDv[kB{fWK\|dILheIV{KG:oIFHCR2czKGGwZDDBRmNDOSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>?	M{OyWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OU[3NVc4Lz5{M{m2O\|E4PzxxYU6=
K562/ABCG2	M1WweWZ2dmO2aX;uJGF{e2G7	NX;RNoRrOC5zLUGwJO69VQ>?	NV\CWVhqOzBibXnu	MWrlcohidmOnczD1dJRic2Vib3[gd5Vje3S{YYTld{Bw\iCDQlPHNkBidmRiQVLDRlEhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI>	NYrySphGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlcyPzdpPkKzPVY4OTd5PD;hQi=>
MCF-7 FLV1000	NF;VS2xMcW6jc3WgRZN{[Xl?	NGTnNmMx6oDVM{CgxtVO	M3rRblUhdWmw	M{[xboRm[3KnYYPld{BcOTJ3SW2tTWFCWCCyaH;0c4xi[mWuaX7nJI9nKEGEQ1KxJIF1KEmFNUCgc4YhOy5\|IN88US=>	NEXKPXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2O\|E4Pyd-MkO5OlcyPzd:L3G+
MCF-7 FLV1000	MWLLbY5ie2ViQYPzZZk>	MY[w5qCUOzBiwsXN	NYr1NVR2PSCvaX6=	MkO3[IVkemWjc3XzJHsyOjWLXT3JRWFRKHCqb4TvcIFj\Wyrbnegc4YhSUKFQkKgZZQhUUN3MDDv[kAxNjB5IN88US=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4N{G3O{c,OjN7NkexO\|c9N2F-
K562/ABCG2	NIHSS2RE\WyuIG\pZYJqdGm2eTDBd5NigXN?	Mn7oNE4yNzBwNT:xJOK2VQ>?	MX[5OkBp	NFPNUXZ{\W6\|aYTpfoV{KEt3NkKvRWJETzJiY3XscJMhfG9ibXn0c5hidnS{b37lJJRweG:2ZXPhcuKh	NX\i[5dnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlcyPzdpPkKzPVY4OTd5PD;hQi=>
8226/MR20	NV;1OIVSS2WubDDWbYFjcWyrdImgRZN{[Xm\|	MmPCNE4yKML3TR?=	MYm5OkBp	MmPid4Vve2m2aYrld{BMPTZ{L1HCR2czKGOnbHzzJJRwKG2rdH;4ZY51em:wZTD0c5BwfGWlYX9CpC=>	MoniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NkexO\|coRjJ\|OU[3NVc4RC:jPh?=
HMC1.1	NYLaZm1CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFjr[mlKSzVyPUG0JI5O	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
HMC1.2	MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXfZNlRJUUN3ME2xO\|I4KG6P	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
p815	NI\sbYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVy1Z\|VnUUN3ME20OFUhdk1?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
Kasumi-1	NVTCZmtrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlTmTWM2OD1\|NjDuUS=>	NW\rVHl1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVc{OTdpPkKzOFk4OzF5PD;hQi=>
M-07e + SCF	Mne5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NF7pZo1KSzVyPUe3JI5O	M2LtT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEm3N\|E4Lz5{M{S5O\|MyPzxxYU6=
EOL-1	MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{KyWmlEPTB;MTDuUS=>	NF76ZWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O\|MyPyd-MkO0PVc{OTd:L3G+
MV4;11	M2TqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NX3XXVAyUUN3MEygNUBvVQ>?	M4HtRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEm3N\|E4Lz5{M{S5O\|MyPzxxYU6=
MOLM14	MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MW\JR\|UxRCBzIH7N	NH;pPFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O\|MyPyd-MkO0PVc{OTd:L3G+
Pat.221	MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{fkT2lEPTB;Nke1JI5O	MnL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUezNVcoRjJ\|NEm3N\|E4RC:jPh?=
Pat.279	NHrLTppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGLSPZdKSzVyPUO0N\|Qhdk1?	NYe0bpY6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVc{OTdpPkKzOFk4OzF5PD;hQi=>
Pat.299	MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkHYTWM2OD15MkS4JI5O	MkX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUezNVcoRjJ\|NEm3N\|E4RC:jPh?=
Pat.305	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2DpemlEPTB;N{C3PUBvVQ>?	NUDKeFVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVc{OTdpPkKzOFk4OzF5PD;hQi=>
Pat.375	M4H2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWLJR\|UxRTVyMzDuUS=>	NXS3cHlTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVc{OTdpPkKzOFk4OzF5PD;hQi=>
Pat.379	MnT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NEnWTndKSzVyPUiwOkBvVQ>?	NWjvSVVsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVc{OTdpPkKzOFk4OzF5PD;hQi=>
Pat.368	NXK4dVhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFqzd\|JKSzVyPUK3NFAhdk1?	M4XpRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEm3N\|E4Lz5{M{S5O\|MyPzxxYU6=
Pat.601	M4TMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M332WWlEPTB;MUG1N{BvVQ>?	NEDF[2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O\|MyPyd-MkO0PVc{OTd:L3G+
HMC1.1	M{TwV2Fxd3C2b4Ppd{BCe3OjeR?=			NHnJ[JpKSzVyPUOxJI5O	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
p815	MofQRZBweHSxc3nzJGF{e2G7			NI\GUVlKSzVyPUO0NUBvVQ>?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
Kasumi-1	M3TmZ2Fxd3C2b4Ppd{BCe3OjeR?=			M1ywTGlEPTB;Nkegcm0>	NVT4eIlIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVc{OTdpPkKzOFk4OzF5PD;hQi=>
M-07e + SCF	NVzvOHVQSXCxcITvd4l{KEG\|c3H5			MXPJR\|UxRTd6IH7N	NYT5c4dSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVc{OTdpPkKzOFk4OzF5PD;hQi=>
EOL-1	NHfqR45CeG:ydH;zbZMhSXO\|YYm=			NULmNGxlUUN3MEygNUBvVQ>?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
MV4;11	MmjhRZBweHSxc3nzJGF{e2G7			NUSyOYg6UUN3ME2yJI5O	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
MOLM14	MWHBdI9xfG:\|aYOgRZN{[Xl?			NWHLRZZlUUN3ME2zJI5O	M1j1blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEm3N\|E4Lz5{M{S5O\|MyPzxxYU6=
GIST822	NWj2cppYSXCxcITvd4l{KEG\|c3H5			NYDHPJVnUUN3ME2xNFkhdk1?	NEXOVmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O\|MyPyd-MkO0PVc{OTd:L3G+
Pat.368	M4DIR2Fxd3C2b4Ppd{BCe3OjeR?=			MnvwTWM2OD1{OUm4JI5O	NX\iXI5nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVc{OTdpPkKzOFk4OzF5PD;hQi=>
Pat.601	M{fBVWFxd3C2b4Ppd{BCe3OjeR?=			NFnTR4JKSzVyPUi3OkBvVQ>?	NYT1d3ZZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVc{OTdpPkKzOFk4OzF5PD;hQi=>
MV4-11	NWjhNYZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUi3NkBp	NFrLVFdKSzVyPUCuN{BvVQ>?	NHjTXoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxNlk{OSd-MkO0NVI6OzF:L3G+
MOLM-14	NWPweY1iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGrrWXk4OiCq	M{e2fWlEPTB;MD6xJI5O	MnLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUK5N\|EoRjJ\|NEGyPVMyRC:jPh?=
SEM-K2	M4Xrfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGj6NlQ4OiCq	MVTJR\|UxRTBwNDDuUS=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzMkmzNUc,OjN2MUK5N\|E9N2F-
RS4;11	NV:ydWZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWfn[2JVPzJiaB?=	MlSxTWM2OD5zMDywNFAhdk1?	M1;oUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEGyPVMyLz5{M{SxNlk{OTxxYU6=
THP-1	MmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4jTXVczKGh?	NFvUdnZKSzVyPkGwMFAxOCCwTR?=	NUfrPZBGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVI6OzFpPkKzOFEzQTNzPD;hQi=>
MV4-11	MlvnRZBweHSxc3nzJGF{e2G7		NGP6dG45NzJ2IHi=	M1;ycYlv\HWlZYOgd4lodmmoaXPhcpQh[W6mIHTvd4Uu\GWyZX7k[Y51KFCDUmCgZ4xm[X[jZ3WgZY5lKGGlY4XteYxifGmxbjDv[kB{fWJvMl6gSG5C	NUDkNFBCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVI6OzFpPkKzOFEzQTNzPD;hQi=>
MOLM-14	NIrvV5BCeG:ydH;zbZMhSXO\|YYm=		MYO4M\|I1KGh?	MknybY5lfWOnczDzbYdvcW[rY3HueEBidmRiZH;z[U1l\XCnbnTlcpQhWEGUUDDjcIVifmGpZTDhcoQh[WOldX31cIF1cW:wIH;mJJN2[i1{TjDEUmE>	Mon5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUK5N\|EoRjJ\|NEGyPVMyRC:jPh?=
SEM-K2	NEnaSIRCeG:ydH;zbZMhSXO\|YYm=		Ml\LPE8zPCCq	MVjpcoR2[2W\|IIPp[45q\mmlYX70JIFv\CCmb4PlMYRmeGWwZHXueEBRSVKSIHPs[YF3[WenIHHu[EBi[2O3bYXsZZRqd25ib3[gd5VjNTKQIFTORS=>	MoXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUK5N\|EoRjJ\|NEGyPVMyRC:jPh?=
AML	NFjlfpJEgXSxdH;4bYNqfHliYYPzZZk>			NVzJOXhnS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSU2OIHPlcIx{KGm\|b3zheIVlKG[{b32gdoVt[XC\|ZXSgZYN2fGVibYnlcI9q\CCuZYXr[Y1q[SCyYYTp[Y51KGijcnLvdolv\yCITGSzJGlVTCCvdYTheIlwdiCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAxODNizszNMi=>	M1LSblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NkW0OFA5Lz5zOU[1OFQxQDxxYU6=
MV4-11	M1\jfmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1\4W\|czKGi{cx?=	NVTkeI5vS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVVZ2LUGxJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSClZXzsJJRqfGW{LXLseYUh[XO\|YYmsJGlEPTBiPTCwMlAxODV4IN88UU4>	NX[yN2lsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm2OVQ1ODhpPkG5OlU1PDB6PD;hQi=>
blast cells	MoPySpVv[3Srb36gZZN{[Xl?		NIDVc5YzKGi{cx?=	NHTmRXlKdmirYnn0bY9vKG:oIF\MWFMhUVSGIH31eIFvfCCjdYTvdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIHLsZZN1KGOnbHzzJIFnfGW{IEKgbJJ{KGK7IHXs[YN1em:laHXtbYx2dWmwZYPj[Y5k\SxiSVO1NEA:KDBwMECwPEDPxE1w	MnvVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl4NUS0NFgoRjF7NkW0OFA5RC:jPh?=
RS4-11	MkjSSpVv[3Srb36gZZN{[Xl?		MWmyJIhzew>?	NIXTcVdKdmirYnn0bY9vKG:oIF\MWFMhUVSGIH31eIFvfCCjdYTvdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGLTOE0yOSClZXzsd{Bi\nSncjCyJIhzeyCkeTDlcIVkfHKxY3jlcYltfW2rbnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAxNjByMUGg{txONg>?	NEjSWGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOU[1OFQxQCd-MUm2OVQ1ODh:L3G+
AML	NX[1Zlh7TnWwY4Tpc44h[XO\|YYm=			MlPkTY5pcWKrdHnvckBw\iCITGSzJIF2fG:yaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hSU2OIHPlcIx{KGm\|b3zheIVlKG[{b32gdoVt[XC\|ZXSgZYN2fGVibYnlcI9q\CCuZYXr[Y1q[SCyYYTp[Y51KGK7IGfld5Rmem5iYnzveJRqdmduIFnDOVAhRSByLkCwNkDPxE1w	NHTlWo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOU[1OFQxQCd-MUm2OVQ1ODh:L3G+
RS4-11	M3XXZWZ2dmO2aX;uJIF{e2G7		NInzU\|gzKGi{cx?=	NETaUWNKdmirYnn0bY9vKG:oIF\MWFMh[XW2b4Doc5NxcG:{eXzheIlwdiCrbjDoeY1idiCUU{StNVEh[2WubIOgZYZ1\XJiMjDodpMh[nliZXzlZ5Rzd2OqZX3pcJVucW6nc3PlcoNmKGG\|c3H5MEBKSzVyIE2gNE4xODR{IN88UU4>	NHXGW3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOU[1OFQxQCd-MUm2OVQ1ODh:L3G+
MV4-11	MVPBcpRqfHWvb4KgZZN{[Xl?	NGruTHUyOCCvZz;r[y=>	M361RVYxKGSjeYO=	NXTxUXFJSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KHinbn;ndoFnfGWmIH3veZNmKG2xZHXsJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geJVud3JicnXndo94fGhiYYSgZZQhOTBibXevb4ctKHCxIE[wJIRigXNicH;zeEB1emWjdH3lcpQ>	MlX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl4NUS0NFgoRjF7NkW0OFA5RC:jPh?=
MV4-11	NGjncGhCdnSrdIXtc5Ih[XO\|YYm=	MnXDNUBu\y:tZz;kZZk>	M{S0TVMxKGSjeYO=	Ml7SRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTW[0MVEyKGOnbHzzJJhmdm:pcnHmeIVlKG2xdYPlJIJwdmVibXHydo94KGWwZ4Lh[pRu\W62IH3v[IVtKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIH3veZNmKGyrZnWgd5BidiCjdDCxJI1oN2upL3ThfUwheG9iZn;yJFMxKGSjeYOgcYVie3W{ZXSgc44h\GG7IEe3JJBwe3RiZH;z[S=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZ3NESwPEc,OTl4NUS0NFg9N2F-
MV4-11	NHXV[\|dCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NV3JV5hyPzJiaILz	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2YND2xNUBk\WyuczDh[pRmeiB5MjDodpMh[nliY3XscEB1cXSncj3icJVmKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMD6wNFA2PiEQvF2u	Mn3zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NUSxPVkoRjF7N{W0NVk6RC:jPh?=
HEK293	NUjSWI5NTnWwY4Tpc44h[XO\|YYm=			MVjCbY5lcW6pIHHm[olvcXS7IITvJGZNXDNiY3H0ZYx6fGmlIHTvcYFqdiCneIDy[ZN{\WRiaX6gTGVMOjl\|IHPlcIx{KGK7IHPvcZBmfGm2aY\lJIJqdmSrbnegZZN{[XluIFvkJF0hOC5yMEG2JO69VS5?	NGnzOYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe1OFE6QSd-MUm3OVQyQTl:L3G+
MV4-11	MVPBcpRqfHWvb4KgZZN{[Xl?	M3fzWVEhdWdxa3e=	MUWyPEBl[Xm\|	MUDBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPVkStNVEh[2WubIOgfIVvd2e{YX\0[YQhcW5iYYTofY1q[yCwdXTlJI1wfXOnIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidIXtc5Ih\3Kxd4ToJIF1KDFibXevb4ctKHCxIGHEJIZweiB{ODDkZZl{KG2nYYP1doVlKGS3cnnu[{Bld3OrbnegdIVzcW:m	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd3NEG5PUc,OTl5NUSxPVk9N2F-
MV4-11	NYTuR5dvSW62aYT1cY9zKGG\|c3H5	NHSxfI8{KG2pL3vn	MX:yPEBl[Xm\|	MW\BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPVkStNVEh[2WubIOgfIVvd2e{YX\0[YQhcW5iYYTofY1q[yCwdXTlJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCC{ZXfy[ZN{cW:wIHH0JFMhdWdxa3esJJBwKFGGIH\vdkAzQCCmYYnzJI1m[XO3cnXkJIFnfGW{IHTvd4lv\yCyZYLpc4Q>	M1TYcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{W0NVk6Lz5zOUe1OFE6QTxxYU6=
MV4-11	Mo\uRY51cXS3bX;yJIF{e2G7	MXixNEBu\y:tZx?=	MXOyPEBl[Xm\|	NVz0fItjSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KHinbn;ndoFnfGWmIHnuJIF1cHmvaXOgcpVl\SCvb4Xz[UBie3Onc4Pl[EBieyC2dX3vdkBoem:5dHigdoVoemW\|c3nvckBifCBzMDDt[{9s\yxicH:gVWQh\m:{IEK4JIRigXNibXXhd5Vz\WRiYX\0[ZIh\G:\|aX7nJJBmemmxZB?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd3NEG5PUc,OTl5NUSxPVk9N2F-
MV4-11	MYfBcpRqfHWvb4KgZZN{[Xl?	M1nCRVMhdWdxa3e=	MkPVNlgh\GG7cx?=	MXvBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPVkStNVEh[2WubIOgfIVvd2e{YX\0[YQhcW5iYYTofY1q[yCwdXTlJI1wfXOnIHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIIT1cY9zKH[xbIXt[UBifCB\|IH3nM4toNCCybzDRSEBnd3JiMkig[IF6eyCvZXHzeZJm\CCjZoTldkBld3OrbnegdIVzcW:m	MnrFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NUSxPVkoRjF7N{W0NVk6RC:jPh?=
MV4-11	Mof1RY51cXS3bX;yJIF{e2G7	NW[1R2dyOTBibXevb4c>	M2LFVlI5KGSjeYO=	NYj3TnY5SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KHinbn;ndoFnfGWmIHnuJIF1cHmvaXOgcpVl\SCvb4Xz[UBie3Onc4Pl[EBieyC\|dYDwdoV{e2mxbjDv[kB1fW2xcjD2c4x2dWViYYSgNVAhdWdxa3esJJBwKFGGIH\vdkAzQCCmYYnzJI1m[XO3cnXkJIFnfGW{IHTvd4lv\yCyZYLpc4Q>	NUXY[2xYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OVQyQTlpPkG5O\|U1OTl7PD;hQi=>
MV4-11	MVrBcpRqfHWvb4KgZZN{[Xl?	NI[zXpQyOCCvZz;r[y=>	MnXlNlgh\GG7cx?=	MUXBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPVkStNVEh[2WubIOgfIVvd2e{YX\0[YQhcW5iYYTofY1q[yCwdXTlJI1wfXOnIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidIXtc5Ih\3Kxd4ToJIF1KDFyIH3nM4toNCCybzDRSEBnd3JiMkig[IF6eyCvZXHzeZJm\CCjZoTldkA{OiCmYYnzJJBwe3Smb4Pl	NFy2bYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe1OFE6QSd-MUm3OVQyQTl:L3G+
MOLM13	Ml70RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTF2xN{Bk\WyuczDlfJBz\XO\|aX7nJGZNXDNvSWTEJI12fGGwdDygS2k2OCB;IECuNFA1KM7:TT6=	NHLFc\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkeyOlk{OSd-MkK3NlY6OzF:L3G+
MV411	M3zYWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NF;4O4U1QCCqcoO=	MVfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNWlQyOSClZXzsd{Bi\nSncjC0PEBpenNiYomgXHRVKGG\|c3H5MEBIUTVyIE2gN{4{OSEQvF2u	MlfLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEiwO\|koRjJ3MUC4NFc6RC:jPh?=
THP1	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGLDOlM1QCCqcoO=	MWXHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDUTHAyKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDYWHQh[XO\|YYmsJGdKPTBiPTC1MlU4PCEQvF2u	NV;n[GJVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFgxPzlpPkK1NVA5ODd7PD;hQi=>
HL60	NHTlPYNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MW[0PEBpenN?	MmTSS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGw3OCClZXzsd{Bi\nSncjC0PEBpenNiYomgXHRVKGG\|c3H5MEBIUTVyIE2gPE4xOTRizszNMi=>	NFzo[FA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwPFA4QSd-MkWxNFgxPzl:L3G+
32D	NXPGXmpKTnWwY4Tpc44h[XO\|YYm=		MmryO\|IhcHK\|	Mk[1TY5pcWKrdHnvckBw\iCqdX3hckBHVFR\|IFnUSEBufXSjboSg[ZhxemW\|c3XkJIlvKG2xdYPlJFMzTCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGdKPTBiPTCwMlAxODBzIN88UU4>	NVjaWoxrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFExOjNpPkK2NFgyODJ\|PD;hQi=>
MV4-11	M1O2eWZ2dmO2aX;uJIF{e2G7		MmG0O\|IhcHK\|	M1PuNWlvcGmkaYTpc44hd2ZiRlzUN{BKXERiaH;tc5p6\2:3czDteZRidnRiaX6gbJVu[W5iTW[0MVEyKGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygS2k2OCB;IECuNFA{KM7:TT6=	NWjaNXBSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFExOjNpPkK2NFgyODJ\|PD;hQi=>
MOLM-13	NWPtV4lNTnWwY4Tpc44h[XO\|YYm=		MknVO\|IhcHK\|	NIPhdmFKdmirYnn0bY9vKG:oIF\MWFMhUVSGIHjleIVzd3q7Z3;1d{BufXSjboSgbY4hcHWvYX6gUW9NVS1zMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEeLNUCgQUAxNjByNDFOwG0v	NWLnZYttRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFExOjNpPkK2NFgyODJ\|PD;hQi=>
32D	MkL1SpVv[3Srb36gZZN{[Xl?		MWm3NkBpenN?	MYfJcohq[mm2aX;uJI9nKGS{dXegdoV{cXO2YX70JIh2dWGwIF\MWFMhUVSGIFS4N\|V[KG23dHHueEBmgHC{ZYPz[YQhcW5ibX;1d4UhOzKGIHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhT0l3MDC9JFAvODF4IN88UU4>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MUCyN{c,OjZyOEGwNlM9N2F-
32D	M2P0SGZ2dmO2aX;uJIF{e2G7		NVXsZZhxPzJiaILz	NVjDU\|U5UW6qaXLpeIlwdiCxZjDkdpVoKHKnc3nzeIFvfCCqdX3hckBHVFR\|IFnUSEBFQDN3VjDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIEOySEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFfJOVAhRSByLkCyO{DPxE1w	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MUCyN{c,OjZyOEGwNlM9N2F-
Sf9	NVOzdWpPTnWwY4Tpc44h[XO\|YYm=		NHW5U\|U1KGi{cx?=	Mmf1TY5pcWKrdHnvckBw\iC5aXzkJJR6eGViR2PUMZRi\2enZDDGUHQ{KGurbnHz[UBld22jaX6gLHk2PjdidH:gV\|k6OyliKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhcW6\|ZXP0JHNnQSClZXzsd{B2e2mwZzDI[ZIzKHCncITp[IUh[XNic4Xid5Rz[XSnIHHmeIVzKDRiaILzJIJ6KEurbnHz[U1IdG9iYYPzZZktKEmFNUCgQUAxNjB4OTFOwG0v	Ml7lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOEGwNlMoRjJ4MEixNFI{RC:jPh?=
32D	MnfiSpVv[3Srb36gZZN{[Xl?		M3e4[VczKGi{cx?=	NYrBfJdJUW6qaXLpeIlwdiCxZjDkdpVoKHKnc3nzeIFvfCCqdX3hckBHVFR\|IFnUSEBFQDN3RjDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIEOySEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFfJOVAhRSByLkG1JO69VS5?	M4KzTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEixNFI{Lz5{NkC4NVAzOzxxYU6=
32D	NYT0cI9vTnWwY4Tpc44h[XO\|YYm=		M4HVO\|czKGi{cx?=	NWLJRXB3UW6qaXLpeIlwdiCxZjDkdpVoKHKnc3nzeIFvfCCqdX3hckBHVFR\|IFnUSEBHPjlzTDDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIEOySEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFfJOVAhRSByLkKyJO69VS5?	NUDIeZM6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFExOjNpPkK2NFgyODJ\|PD;hQi=>
Sf9	NUfjV\|ZWTnWwY4Tpc44h[XO\|YYm=		MV[xNlAhdWmwcx?=	NV;YcJM1UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBIW1RvdHHn[4VlKF[HR1\SNkBscW6jc3Wg[I9u[WmwIDjWO\|g6KHSxIG[xN\|U3MSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDpcpNm[3RiU3[5JINmdGy\|IIXzbY5oKHCxbInHcJU1QlS7cjDw[ZB1cWSnIHHzJJN2[nO2cnH0[UBi\nSncjCxNlAhdWmwczDifUBMcW6jc3WtS4xwKGG\|c3H5MEBKSzVyIE2gNE41OyEQvF2u	NWntRng4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFExOjNpPkK2NFgyODJ\|PD;hQi=>
RS4:11	MW\GeY5kfGmxbjDhd5NigQ>?		MWe3NkBpenN?	M3zNeGlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIHjvcY97gWexdYOgSmxVOyCrbjDoeY1idiCUU{S6NVEh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDHTVUxKD1iMj6yJO69VS5?	NF:wVFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NVAzOyd-Mk[wPFExOjN:L3G+
MV4-11	MkLQRY51cXS3bX;yJIF{e2G7	NFPqPFYyOCCvZz;r[y=>	NHnCR5U1QCCmYYnz	MoP4RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTW[0MVEyKGOnbHzzJJhmdm:pcnHmeIVlKGmwIH71[IUhdW:3c3WgZZN{\XO\|ZXSgZZMhfHWvb4KgdoVoemW\|c3nvckBifCBzMDDt[{9s\yxicH:gdYQh[WSvaX7pd5RmemWmIH;uJIRigSBzIITvJFUhdWWjc4Xy[YQh\HW{aX7nJFQ5KGSjeYOgdI9{fCCuYYP0JIRwe2V?	M3TSeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEixNFI{Lz5{NkC4NVAzOzxxYU6=
MV4-11	NF30epNCdnSrdIXtc5Ih[XO\|YYm=	NFHHcm4yOCCvZz;r[y=>	MlT2OFgh\GG7cx?=	MoXERY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTW[0MVEyKGOnbHzzJJhmdm:pcnHmeIVlKGmwIH71[IUhdW:3c3WgZZN{\XO\|ZXSgZZMhfHWvb4KgdoVoemW\|c3nvckBifCBzMDDt[{9s\yxicH:gdYQh[WSvaX7pd5RmemWmIH;uJIRigSB6IITvJFEzKG2nYYP1doVlKGS3cnnu[{A1QCCmYYnzJJBwe3RibHHzeEBld3On	MmrRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOEGwNlMoRjJ4MEixNFI{RC:jPh?=
MV4-11	MkjvR5l1d3SxeHnjbZR6KGG\|c3H5		MXW3NkBpenN?	M4fOR2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1XPC1zMTDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjByME[4JO69VS5?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF2MkOxO{c,OjZzNEKzNVc9N2F-
Sf21	MnizSpVv[3Srb36gZZN{[Xl?		NFS0[24yPSCvaX7z	M{DqR2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iRlzUN{BmgHC{ZYPz[YQhcW5iaX7z[YN1KFOoMkGgZ4VtdHNicILlbY5kfWKjdHXkJIZweiBzNTDtbY5{KG[xbHzve4VlKGK7IIDvcJkpT2y3OmT5dkkhe3Wkc4TyZZRmKGGmZHn0bY9vKG[xcjCzNEBucW6\|IHnuJJBz\XOnbnPlJI9nKFupYX3tZU0{OlCfQWTQJIJ6KFSULV\SSXQh[XO\|YYmsJGlEPTBiPTCwMlAzPjB6IN88UU4>	NHzXTXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G4O\|g3OCd-MkexPFc5PjB:L3G+
MV4-11	M{LQTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGi1[2s1QCCqcoO=	MnLuS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUXY1NTFzIHPlcIx{KGW6cILld5NqdmdiRlzUN{1KXERiYX\0[ZIhPDhiaILzJIJ6KFiWVDDhd5NigSxiR1m1NEA:KDFwMUCzJO69VS5?	NFf2PIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G4O\|g3OCd-MkexPFc5PjB:L3G+
HL60	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3f2fFQ5KGi{cx?=	NFLWW3VIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJVDZyIHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIF\MWE0{KGGodHXyJFQ5KGi{czDifUBZXFRiYYPzZZktKEeLNUCgQUAyNjR6ODFOwG0v	M{DwSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUi3PFYxLz5{N{G4O\|g3ODxxYU6=
THP1	NWjIOoZ5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWK0PEBpenN?	NYmw[mxZT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hXEiSMTDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDGUHQuOyCjZoTldkA1QCCqcoOgZpkhYFSWIHHzd4F6NCCJSUWwJF0hOi5zMkWg{txONg>?	M2HMWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUi3PFYxLz5{N{G4O\|g3ODxxYU6=
K562	M3TjS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NF;z[Xk1QCCqcoO=	MluyS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gT\|U3OiClZXzsd{Bi\nSncjC0PEBpenNiYomgXHRVKGG\|c3H5MEBIUTVyIE2gNk43OzhizszNMi=>	M1TNVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUi3PFYxLz5{N{G4O\|g3ODxxYU6=
Sf21	MWfGeY5kfGmxbjDhd5NigQ>?		MVexNEBucW6\|	MljLTY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFfTWE11[WepZXSgdoVkd22kaX7hcpQhcHWvYX6ge4lt\C22eYDlJGZNXDNiKEW2OEB1dyCnbnSgdoV{cWS3ZYOpJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDz[lIyKGOnbHzzJJV{cW6pIFHicJRq\GViYYOgd5Vje3S{YYTlJIlvKHC{ZYPlcoNmKG:oIGvnZY1u[TN\|UG3BWHAh[W[2ZYKgNVAhdWmwczDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pIH3leIhw\CxiSVO1NEA:KDBwMEK1OUDPxE1w	NX\3bW5iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwOFM4QTRpPkK4NFQ{Pzl2PD;hQi=>
Sf21	MoO5SpVv[3Srb36gZZN{[Xl?		MX6xNEBucW6\|	NGfhXZdKdmirYnn0bY9vKG:oIF6teIVzdWmwYXygS3NVNXSjZ3fl[EBz\WOxbXLpcoFvfCCqdX3hckB4cWymLYT5dIUhTkyWMzCoOVY1KHSxIHXu[EBz\XOrZIXld{khTDh\|NWmgcZV1[W62IHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CC\|ZkKxJINmdGy\|IIXzbY5oKEGkbITp[IUh[XNic4Xid5Rz[XSnIHnuJJBz\XOnbnPlJI9nKFupYX3tZVM{WF2DVGCgZYZ1\XJiMUCgcYlveyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oKG2ndHjv[EwhUUN3MDC9JFAvOjN3NTFOwG0v	NF60dZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEC0N\|c6PCd-MkiwOFM4QTR:L3G+
MV4-11	NWjPUG9JT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MlfYS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUXY1NTFzIHPlcIx{KGijcnLvdolv\yCITGSzMWlVTCCvdYThcpQh[nliWGTUJIF{e2G7LDDHTVUxKD1iMT6xNFMh\|ryPLh?=	NXm3TWhPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwOFM4QTRpPkK4NFQ{Pzl2PD;hQi=>
THP1	Mny5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MlT6S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gWGhROSClZXzsd{Bp[XKkb4Lpcochf2muZD30fZBmKE[OVEOgZpkhYFSWIHHzd4F6NCCJSUWwJF0hOi5zMkWg{txONg>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB2M{e5OEc,OjhyNEO3PVQ9N2F-
BAF3	M1jHemFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NWXPeWR{PzJiaILz	NWLzdXVHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIhiemKxcnnu[{BHVFR\|LVnUSE1FQDN3RzDteZRifGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IECuNFAxOyEQvF2u	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3	M4jieGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NF;neIg4OiCqcoO=	NELKRldCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgbIFz[m:{aX7nJGZNXDNvSWTEMWQ5OzWDIH31eIF1cW:wIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDHTVUxKD1iMD6wNFA{KM7:TT6=	NXradYE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
BAF3	Mn[yRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MXq3NkBpenN?	NELvSnVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgbIFz[m:{aX7nJGZNXDNvREizOWghdXW2YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEeLNUCgQUAxNjByMEOg{txONg>?	NWH6[4Z1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
MOLM13	MoX0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M4PWd\|czKGi{cx?=	MX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTF2xN{Bk\WyuczDoZZJjd3KrbnegSmxVOy2LVFSgcZV1[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGdKPTBiPTCwMlAxODNizszNMi=>	NH7CfpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
BAF3	MoX6RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MoiwO\|IhcHK\|	MnuxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHX4dJJme3OrbnegWGVNNW[3c3XkJGZNXDNia3nuZZNmKGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCJSUWwJF0hOC5yMECzJO69VS5?	NWLjfXNlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
BAF3	NITNcZhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MnvVO\|IhcHK\|	NV;aem1ISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIhiemKxcnnu[{BHVFR\|LVnUSE1FQDN3TjDteZRifGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IECuNFAxOyEQvF2u	M1PwV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
MOLM14	MXPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NH;vOWs4OiCqcoO=	NFvXVlFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yPCClZXzsd{Bp[XKkb4LpcochTkyWMz3JWGQhdXW2YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEeLNUCgQUAxNjByMEOg{txONg>?	M4\yblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
BAF3	NIPufVNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NU\hPFUzPzJiaILz	NFPJb\|RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgbIFz[m:{aX7nJGZNXDNvSWTEJI12fGG2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE4xODB\|IN88UU4>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
MV4-11	MkLZRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MkO0O\|IhcHK\|	NYnkd\|hJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNWlQuOTFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEeLNUCgQUAxNjByMEOg{txONg>?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3	NYf5[Y1lSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mny3O\|IhcHK\|	M17h[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgWGVNNW[3c3XkJHBFT0[UYXzwbIEufHKjboPmc5Ju\WRibX;1d4UhSkGIMzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiR1m1NEA:KDBwMECwN{DPxE1w	NXLqeGp5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
BAF3	MoXrRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M1TPXFczKGi{cx?=	NGnL[nVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgbIFz[m:{aX7nJGZNXDNvREizOXkhdXW2YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEeLNUCgQUAxNjByMjFOwG0v	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3	NX;WR25jSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3TRVlczKGi{cx?=	NULqdYg2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBVTUxvZoXz[YQhWESJRmLi[ZRiNXS{YX7z[o9zdWWmIH3veZNmKEKDRkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSByLkCwOFQh\|ryPLh?=	M1WxV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
BAF3	M2TYOmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M{HSdlczKGi{cx?=	NVm1eZJ5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIhiemKxcnnu[{BHVFR\|LVS4N\|VXKG23dHH0bY9vKGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCJSUWwJF0hOC5yMUGg{txONg>?	MknxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
BAF3	M1;3U2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MVO3NkBpenN?	NYfDO2xSSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIhiemKxcnnu[{BHVFR\|LVnUSE1FQDN3ZHXsJI12fGG2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE4xOTJizszNMi=>	NEnLTos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
Sf9	NUjsNmNYTnWwY4Tpc44h[XO\|YYm=		M3LPTVEhcHJ?	MknMTY5pcWKrdHnvckBw\iCqdX3hckBOXjRvMUGgZ4VtdHNvZHXybZZm\CCKaYOteIFo\2WmIF\MWFMhUVSGIH31eIFvfCBqNU[0JJRwKDl7MzDy[ZNq\HWnczmg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIIPmPUBk\WyuczD1d4lv\yCyb3z5JEg1QjFiR3z1MEBVgXJrIHHzJJN2[nO2cnH0[UBi\nSncjCxJIhzKGK7IFHEVE1IdG9ia3nuZZNmKGG\|c3H5MEBKSzVyIE2gNE4xOTZ6IN88UU4>	NEjTXGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
BAF3	NIrDdZdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MXS3NkBpenN?	MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGTFUE1nfXOnZDDjT2lVNXS{YX7z[o9zdWWmIH3veZNmKEKDRkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSByLkCxO{DPxE1w	M4rUWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
BAF3	MoLhRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MkLUO\|IhcHK\|	NHrGcnVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHRGVC2odYPl[EBEW0ZzUj30doFve2[xcn3l[EBud3W\|ZTDCRWY{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE4xOjRizszNMi=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3	NGfDe5BCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MmfPO\|IhcHK\|	MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiaHHyZo9zcW6pIF\MWFMuUVSGLVS4N\|V[KG23dHH0bY9vKGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCJSUWwJF0hOC5yMkig{txONg>?	M{W1elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
Sf9	NHW1SWVHfW6ldHnvckBie3OjeR?=		MYixJIhz	NEfBNodKdmirYnn0bY9vKG:oIHj1cYFvKEiONkCgZ4VtdHNvZHXybZZm\CCKaYOteIFo\2WmIF\MWFMhMDV4NDD0c{A6QTNicnXzbYR2\XNrIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CC\|ZkmgZ4VtdHNidYPpcocheG:ueTCoOFoyKEeudTygWJlzMSCjczDzeYJ{fHKjdHWgZYZ1\XJiMTDodkBjgSCDRGCtS4xwKGurbnHz[UBie3OjeTygTWM2OCB;IECuNFMxPCEQvF2u	NIjM[FM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
BAF3	NIfae21CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M13SUVczKGi{cx?=	M2m4dWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDoZZJjd3KrbnegSmxVOy2LVFStSFg{PUlibYX0ZZRqd25iYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSByLkC1OkDPxE1w	NYruc40yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
BAF3	NEHHTnFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3LhW\|czKGi{cx?=	MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGTFUE1nfXOnZDDESHIzNXS{YX7z[o9zdWWmIH3veZNmKEKDRkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSByLkGxJO69VS5?	M4DuNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
BAF3	Mke1RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MofZO\|IhcHK\|	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGTFUE1nfXOnZDDESHIyNXS{YX7z[o9zdWWmIH3veZNmKEKDRkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSByLkGyJO69VS5?	M3vWfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
CMK	MX7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NH\Md2c4OiCqcoO=	MkCwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFTVugZ4VtdHNiZYjwdoV{e2mwZzDGUHQ{KGurbnHz[UBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvOTJizszNMi=>	NVPieYFpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
BAF3	Mnq3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NVHuWmlmPzJiaILz	NX\xcG1LSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBVTUxvZoXz[YQhWkWWLYTyZY5{\m:{bXXkJI1wfXOnIFLBSlMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGdKPTBiPTCwMlE{KM7:TT6=	NHXBXY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
HL60	NIqzcm5CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MmfTO\|IhcHK\|	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiZYjwdoV{e2mwZzDGUHQ{KGurbnHz[UBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvOTNizszNMi=>	M1m1TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
BAF3	M2TFOmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M1PsT\|czKGi{cx?=	MX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGTFUE1nfXOnZDDGUHQ1NXS{YX7z[o9zdWWmIH3veZNmKEKDRkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSByLkK3JO69VS5?	MnKwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
BAF3	NWjoOWN3SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3L5e\|czKGi{cx?=	Mm[4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHjhdoJwemmwZzDGUHQ{NUt4NkPRJI12fGG2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE4{PyEQvF2u	NHXXTFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
BAF3	MWjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MXS3NkBpenN?	NYjwVY5USW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBVTUxvZoXz[YQhVEONLYTyZY5{\m:{bXXkJI1wfXOnIFLBSlMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGdKPTBiPTCwMlQh\|ryPLh?=	Mk\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
U937	MUPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NWXBZWcxPzJiaILz	NYLVRlBySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPVM4KGOnbHzzJIV5eHKnc4PpcochTkyWMzDrbY5ie2ViYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSBzLkKg{txONg>?	NYr2UpBGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
SKM1	MoLwRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NFXEe204OiCqcoO=	NFTlW5ZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLUVEh[2WubIOg[ZhxemW\|c3nu[{BHVFR\|IHvpcoF{\SCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiR1m1NEA:KDFwMzFOwG0v	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
NB4	NV;mRZIySW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NY\mdnhmPzJiaILz	MnPaRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQkSgZ4VtdHNiZYjwdoV{e2mwZzDGUHQ{KGurbnHz[UBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFcvOyEQvF2u	NEjPXHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
MOLM13	MXrD[YxtKGO7Y3zlJIF{e2G7	M3zDVlExOCCwTR?=	MnrJNVIhcHK\|	Mn\DR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gUW9NVTF\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBifCCJMD;HNUBxcGG\|ZTDheEAyODBibl2gZYZ1\XJiMUKgbJJ{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQuTkGFUzDhcoFtgXOrcx?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
MOLM14	Mnn2R4VtdCCleXPs[UBie3OjeR?=	MWCxNFAhdk1?	NV\EWnNoOTJiaILz	MnHUR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gUW9NVTF2IHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBifCCJMD;HNUBxcGG\|ZTDheEAyODBibl2gZYZ1\XJiMUKgbJJ{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQuTkGFUzDhcoFtgXOrcx?=	NVfBTGJiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
MOLM13	NWHWdodZSXCxcITvd4l{KGG\|c3H5	MoPVNVAxKG6P	NVPSc4hJOTJiaILz	MX3JcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKE2RTF2xN{Bk\WyuczDhd5Nme3OnZDDhd{BkdGWjdnHn[UBw\iCSQWLQJIF1KDFyMDDuUUBi\nSncjCxNkBpenNiYomgbY1ufW6xYnzveJRqdmdibXX0bI9l	M3LYPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
MV4-11	M3vseGFxd3C2b4Ppd{Bie3OjeR?=	NUi5U5V{OTByIH7N	M1zKZ\|Q5KGi{cx?=	M4HYN2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTW[0MVEyKGOnbHzzJIF{e2W\|c3XkJIF{KGOuZXH2ZYdmKG:oIGDBVnAh[XRiMUCwJI5OKGGodHXyJFQ5KGi{czDifUBqdW23bn;icI91fGmwZzDt[ZRpd2R?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
MOLM13	M{fneGFxd3C2b4Ppd{Bie3OjeR?=	MX6xNFAhdk1?	MVOxNkBpenN?	NIXYcZVKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF3PUG0yOyClZXzsd{Bie3Onc4Pl[EBieyClbHXheoFo\SCxZjDjZZNx[XOnLUOgZZQhOTByIH7NJIFnfGW{IEGyJIhzeyCkeTDpcY12dm:kbH;0eIlv\yCvZYToc4Q>	NYLXWJVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
MOLM14	M3f4XWFxd3C2b4Ppd{Bie3OjeR?=	MlvkNVAxKG6P	MWCyOEBpenN?	M1ntZWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTV;MUVE1KGOnbHzzJIF{e2W\|c3XkJIF{KGOuZXH2ZYdmKG:oIGDBVnAh[XRiMUCwJI5OKGGodHXyJFI1KGi{czDifUBqdW23bn;icI91fGmwZzDt[ZRpd2R?	M3PmZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
MOLM14	M3fHV2Fxd3C2b4Ppd{Bie3OjeR?=	M3GzZ\|ExOCCwTR?=	M4fXcFI1KGi{cx?=	NUW3fGw{UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDNU2xOOTRiY3XscJMh[XO\|ZYPz[YQh[XNiY3zlZZZi\2Vib3[gZ4F{eGG\|ZT2zJIF1KDFyMDDuUUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveJRqdmdibXX0bI9l	MkGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
MV4-11	M1faSGFxd3C2b4Ppd{Bie3OjeR?=	MV2xNFAhdk1?	M{XNPVQ5KGi{cx?=	MYfJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKE2YND2xNUBk\WyuczDhd5Nme3OnZDDhd{BkdGWjdnHn[UBw\iClYYPwZZNmNTNiYYSgNVAxKG6PIHHmeIVzKDR6IHjyd{BjgSCrbX31co9jdG:2dHnu[{Bu\XSqb3S=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
MV4-11	M4\Nc2NmdGxiY4njcIUh[XO\|YYm=	MWSxNFAhdk1?	NGHoUHIyOiCqcoO=	NWrZV\|JDS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hVVZ2LUGxJINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNE9IOSCyaHHz[UBifCBzMECgcm0h[W[2ZYKgNVIhcHK\|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZoF{\WRvRlHDV{BidmGueYPpdy=>	M4H5PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
Saos-2	NULKS2w1eUiWUzDhd5NigQ>?			M{\vNJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	NEPaSlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	NH76[21yUFSVIHHzd4F6			MUPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN?	NYn1W4dnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12	MX7xTHRUKGG\|c3H5			NG\vU45yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBDXC1zMjDj[Yxtew>?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	MVjxTHRUKGG\|c3H5			MULxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDMRW4uPSClZXzsdy=>	NIDidFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	MVvxTHRUKGG\|c3H5			NXLRfWRWeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	MmTjdWhVWyCjc4PhfS=>			Ml;qdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2VSDDj[Yxtew>?	NFrUSpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	M4LWZ5FJXFNiYYPzZZk>			M{\XXJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGE3PzNiY3XscJMq	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-37	MWnxTHRUKGG\|c3H5			MWrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDCWE0{PyClZXzsdy=>	MkT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
U-2 OS	NF3LdWNyUFSVIHHzd4F6			NGj4b\|JyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBWNTJiT2OgZ4VtdHN?	Ml3OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	MXTxTHRUKGG\|c3H5			M2HnW5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG9JWy13MDDj[Yxtew>?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	Mmm4dWhVWyCjc4PhfS=>			MVfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFQyKGOnbHzz	NV2zOnNORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2	NYCwRmRJeUiWUzDhd5NigQ>?			M2TJWJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	NXTrdG9FeUiWUzDhd5NigQ>?			MUPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	MV7xTHRUKGG\|c3H5			M1zRfpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz	NWnMWmtPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	NF7RXXByUFSVIHHzd4F6			MnjhdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIyPjR\|IHPlcIx{	NIP2dpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NF34bZdyUFSVIHHzd4F6			NFzNUm9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLV3DJINmdGy\|	NVvYS\|BkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2	NYDwdIV7eUiWUzDhd5NigQ>?			MV\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTTk1ISk1{IHPlcIx{	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
TC32	MkHFdWhVWyCjc4PhfS=>			NX\kcZlseUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtew>?	MlzOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MOLM13	NEnoVY1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MoC1O\|IhcHK\|	MWnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNU2xOOTNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JINidGOnaX6gRW0h\HmnLXLhd4VlKG[udX;y[ZNk\W6lZTDhd5NigSxiR1m1NEA:KDBwMECyJO69VS5?	MkHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4N{KwOFkoRjJ7NkeyNFQ6RC:jPh?=
MV4-11	NEnHbG9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MlPxO\|IhcHK\|	MlL2S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUXY1NTFzIHPlcIx{KGGodHXyJFczKGi{czDifUBk[WylZXnuJGFOKGS7ZT3iZZNm\CCobIXvdoV{[2WwY3WgZZN{[XluIFfJOVAhRSByLkCwN{DPxE1w	M3qyblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkeyNFQ6Lz5{OU[3NlA1QTxxYU6=
BA/F3	NIXJNVhHfW6ldHnvckBie3OjeR?=		M3zPV\|czKGi{cx?=	M4DrU2lvcGmkaYTpc44hd2ZiRlzUN{BKXERibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkhfHKjboPm[YN1\WRiaX6gcY92e2ViQlGvSlMh[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JINidGOnaX6gRW0h\HmnLXLhd4VlKG[udX;y[ZNk\W6lZTDhd5NigSxiR1m1NEA:KDBwMEC3JO69VS5?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ5MkC0PUc,Ojl4N{KwOFk9N2F-
Sf9	MljxSpVv[3Srb36gZZN{[Xl?			M1jTbGlvcGmkaYTpc44hd2ZiTj30[ZJucW6jbDDHV3QwUGm\|Nj3meZNm\CC{ZXPvcYJqdmGwdDDoeY1idiCITGSzJEhTPTdzIITvJHM6QTNicnXzbYR2\XNrIFnUSEBufXSjboSg[ZhxemW\|c3XkJIlvKFOoOTDpcpNm[3RiY3XscJMhfXOrbnegdI9tgSBqQXzhMGdtfSyOeYOsWJlzMSB4OkK6OVoyKGi7ZILvZpJwdWmmZTDhd{B{fWK\|dILheIUhcW5icILld4Vv[2Vib3[gX4didW2jLUOzVH1CXFBuIFnDOVAhRSByLkCxJO69VS5?	M3jWSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkeyNFQ6Lz5{OU[3NlA1QTxxYU6=
Sf9	M{HuTmZ2dmO2aX;uJIF{e2G7			NGS1SnFKdmirYnn0bY9vKG:oIF6teIVzdWmwYXygS3NVN0irc{[t[pV{\WRicnXjc41jcW6jboSge4lt\CC2eYDlJIh2dWGwIF\MWFMhMFJ3N{GgeI8hWzl7MzDy[ZNq\HWnczmg[ZhxemW\|c3XkJIlvKFOoOTDpcpNm[3RiY3XscJMhfXOrbnegdI9tgSBqQXzhMGdtfSyOeYOsWJlzMSB4OkK6OVoyKGi7ZILvZpJwdWmmZTDhd{B{fWK\|dILheIUhcW5icILld4Vv[2Vib3[gX4didW2jLUOzVH1CXFBuIFnDOVAhRSByLkCzOkDPxE1w	NXG1RYxrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2O\|IxPDlpPkK5OlczODR7PD;hQi=>
Kasumi-1	M1\rcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWPGVnNuPzJiaILz	M1zJcmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGtie3WvaT2xJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSClYXzj[YlvKEGPIHT5[U1j[XOnZDDmcJVwemW\|Y3XuZ4Uh[XO\|YYmsJGdKPTBiPTCwMlA3PCEQvF2u	NYnhW2R1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2O\|IxPDlpPkK5OlczODR7PD;hQi=>
Sf9	M1jCVmZ2dmO2aX;uJIF{e2G7			MnLqTY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFfTWE9JcXN4LX\1d4VlKHKnY3;tZolv[W62IHj1cYFvKE[OVEOgLHI2PzFidH:gV\|k6OyC{ZYPp[JVmeyliREizOXkhdXW2YX70JIV5eHKnc4Pl[EBqdiCVZkmgbY5{\WO2IHPlcIx{KHW\|aX7nJJBwdHliKFHsZUxIdHVuTInzMHR6eiliNkqyPlU7OSCqeXTyc4Jzd22rZHWgZZMhe3Wkc4TyZZRmKGmwIIDy[ZNmdmOnIH;mJHto[W2vYT2zN3BeSVSSLDDJR\|UxKD1iMD6xN\|Yh\|ryPLh?=	NIjTWpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[3NlA1QSd-Mkm2O\|IxPDl:L3G+
BA/F3	NH\YcJJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Ml3LO\|IhcHK\|	MUnHdo94fGhiaX7obYJqfGmxbjDv[kBud3W\|ZTDCRU9HOyClZXzsd{Bi\nSncjC3NkBpenNiYomgZ4Ft[2WrbjDBUUBlgWVvYnHz[YQh\my3b4Lld4NmdmOnIHHzd4F6NCCJSUWwJF0hOS52NUKg{txONg>?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ5MkC0PUc,Ojl4N{KwOFk9N2F-
MV4-11	MUHGeY5kfGmxbjDhd5NigQ>?	NWWyWXZrOC5yMTD0c{AyODBibl2=	MmXYNUBpeg>?	MXvJcohq[mm2aX;uJI9nKE[OVEOgTXRFKG23dHHueEBqdiCqdX3hckBOXjRvMUGgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hSUuWIIDoc5NxcG:{eXzheIlwdiCjdDDTOFc{KGG2IECuNFEhfG9iMUCwJI5OKGGodHXyJFEhcHJiYomgbY1ufW6xYnzveEBidmGueYPpdy=>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ5MkC0PUc,Ojl4N{KwOFk9N2F-
MV4-11	MXXGeY5kfGmxbjDhd5NigQ>?	NYfybXFqOC5yMTD0c{AyODBibl2=	MW[xJIhz	NGDiblZKdmirYnn0bY9vKG:oIF\MWFMhUVSGIH31eIFvfCCrbjDoeY1idiCPVkStNVEh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iTVXLNU8zKHCqb4PwbI9zgWyjdHnvckBifCCVMkG3M\|IzOSCjdDCwMlAyKHSxIEGwNEBvVSCjZoTldkAyKGi{IHL5JIludXWwb3Lsc5Qh[W6jbInzbZM>	M2T0S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkeyNFQ6Lz5{OU[3NlA1QTxxYU6=
MV4-11	MYTGeY5kfGmxbjDhd5NigQ>?	NUP4dJUyOSCwTR?=	NHHLU44yKGi{	M3GxTWlvcGmkaYTpc44hd2ZiRlzUN{BKXERibYX0ZY51KGG3dH;wbI9{eGixconsZZRqd25iYYSgXVU5QS93OUGgbY4hcHWvYX6gUXY1NTFzIHPlcIx{KGG2IEGgcm0h[W[2ZYKgNUBpeiCkeTDpcY12dm:kbH;0JIFv[Wy7c3nz	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ5MkC0PUc,Ojl4N{KwOFk9N2F-
MV4-11	MmqwSpVv[3Srb36gZZN{[Xl?	M4f3elEhdk1?	M{LFS\|EhcHJ?	NV7lfFljUW6qaXLpeIlwdiCxZjDGUHQ{KEmWRDDteZRidnRiYYX0c5Bpd3OyaH;yfYxifGmxbjDheEB[QDR{IHnuJIh2dWGwIF3WOE0yOSClZXzsd{BifCBzIH7NJIFnfGW{IEGgbJIh[nliaX3teY5w[myxdDDhcoFtgXOrcx?=	MkjTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4N{KwOFkoRjJ7NkeyNFQ6RC:jPh?=
MV4-11	Mn3NSpVv[3Srb36gZZN{[Xl?	MofSNE4xOSC2bzCxNFAhdk1?	MlP6NUBpeg>?	M4L5SGlvcGmkaYTpc44hd2ZiRlzUN{BKXERibYX0ZY51KGmwIHj1cYFvKE2YND2xNUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCVVFHUOUBxcG:\|cHjvdplt[XSrb36gZZQhYTZ7NDDheEAxNjBzIITvJFExOCCwTTDh[pRmeiBzIHjyJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN?	NInWTJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[3NlA1QSd-Mkm2O\|IxPDl:L3G+
MV4-11	NFTUWGlHfW6ldHnvckBie3OjeR?=	NXzoV4tkOC5yMTD0c{AyODBibl2=	NIfoNJAyKGi{	MoTBTY5pcWKrdHnvckBw\iCITGSzJGlVTCCvdYThcpQhcW5iaIXtZY4hVVZ2LUGxJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKEWUS{GvNkBxcG:\|cHjvdplt[XSrb36gZZQhXDJyMj;ZNlA1KGG2IECuNFEhfG9iMUCwJI5OKGGodHXyJFEhcHJiYomgbY1ufW6xYnzveEBidmGueYPpdy=>	M17ZW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkeyNFQ6Lz5{OU[3NlA1QTxxYU6=
MV4-11	MlTISpVv[3Srb36gZZN{[Xl?	NV7FNJB1OTBibXevb4c>	NYnadVJzOjRiaILz	NUHPZmtsUW5idnn2c{BqdmirYnn0bY9vKG:oIF\MWFMhUVSGIH31eIFvfCCrbjDoeY1idiCPVkStNVEh[2WubIOgfIVvd2e{YX\0[YQhcW5iYYTofY1q[yCwdT;ueUBud3W\|ZTDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCVVFHUOUBxcG:\|cHjvdplt[XSrb36gZZQhYTZ7NDDheEAyOCCvZz;r[{whcXBiYX\0[ZIhOjRiaILzJIJ6KGmvbYXuc4Jtd3RibXX0bI9lKHKnbHH0bZZmKHSxIHPvcpRzd2x?	M3LWc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkeyNFQ6Lz5{OU[3NlA1QTxxYU6=
MV4-11	Ml7DSpVv[3Srb36gZZN{[Xl?	MWiwMlEhfU1?	M3HQSFQhcHK\|	NEL5VlNKdmirYnn0bY9vKG:oIF\MWFMhcW5iaIXtZY4hVVZ2LUGxJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCDS2SgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejR5MzDy[ZNq\HWnIHH0JFAvOSC3TTDh[pRmeiB2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	MnrCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6OUS5OFQoRjJ7OEm0PVQ1RC:jPh?=
MV4-11	NIrwVXhHfW6ldHnvckBie3OjeR?=	M4nK[lAvOSC3TR?=	NVjzS5lMPCCqcoO=	MWXJcohq[mm2aX;uJI9nKE[OVEOgbY4hcHWvYX6gUXY1NTFzIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBUXEGWNTDwbI9{eGixconsZZRqd25iYYSgWJlzPjl2IILld4llfWViYYSgNE4yKHWPIHHmeIVzKDRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	NYDDdXNnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4PVQ6PDRpPkK5PFk1QTR2PD;hQi=>
MV4-11	MlrqSpVv[3Srb36gZZN{[Xl?	MWOwMlEhfU1?	MWG0JIhzew>?	M1zybWlvcGmkaYTpc44hd2ZiRlzUN{BqdiCqdX3hckBOXjRvMUGgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEWUS{GvNkBxcG:\|cHjvdplt[XSrb36gZZQhXGi{MkCyM3R6ejJyNDDy[ZNq\HWnczDheEAxNjFidV2gZYZ1\XJiNDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NYH1eXdIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4PVQ6PDRpPkK5PFk1QTR2PD;hQi=>
MV4-11	NGjuXZVHfW6ldHnvckBie3OjeR?=	NH65eVkxNjFidV2=	NXjXSGU1PCCqcoO=	MUnJcohq[mm2aX;uJI9nKE[OVEOgdIhwe3Cqb4L5cIF1cW:wIHH0JHR6ejV6OT:1PVEhemW\|aXT1[ZMhcW5iaIXtZY4hVVZ2LUGxJINmdGy\|IHH0JFAvOSC3TTDh[pRmeiB2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTh7NEm0OEc,Ojl6OUS5OFQ9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-STAT5 / STAT5 / β-catenin / p-AKT / AKT / p-ERK / ERK / p-S6 / S6; PubMed: 28625976 Cancer Res Western blot analysis of AC220 treated MV4-11 cells. Cells were starved for overnight and treated with AC220 at indicated concentrations. Cells were harvested after 2 hours treatment and lysed. Then western blots analysis was performed. The quantification of bands are shown below the gel. phospho-FLT3 / FLT3; PubMed: 22875611 Haematologica (B) The same cells were also harvested for Western blot analysis after treatment for 90 min with different concentrations of AC220. The phosphorylation of the different FLT3 proteins was determined using a phospho-FLT3 antibody.	28625976 22875611
Immunofluorescence	WGA / FLT3 ; PubMed: 28895560 Leukemia Immunofluorescence staining of FLT3-WT, FLT3 mutants or empty vector with or without AC220 treatment in transiently transfected U2OS cells. WGA (wheat germ agglutinin). Scale bar: 25 μm.	28895560
Growth inhibition assay	Cell viability; PubMed: 23967177 PLoS One K562/ABCB1 and K562/ABCG2 cells exhibit collateral sensitivity toquizartinib. K562, K562/ABCB1 and K562/ABCG2 cells were plated in the presence of quizartinib in increasing concentrations for 96 hours and viable cells were measured using the WST-1 assay.	23967177

体内研究

AC220作用于移植瘤模型，具有好的药品属性，极高的药效和耐受性。在体内，AC220作用于FLT3-ITD AML鼠模型，抑制FLT3活性,明显延长寿命；作用于依赖FLT3的移植瘤鼠模型时，根除肿瘤；作用于病人原代细胞时，有效抑制FLT3活性。^[1]

激酶实验：^[1]	- 合并激酶实验: 为了测定AC220抑制无靶点激酶的效果，为了比较AC220和其他FLT抑制剂的选择性,使AC220作用于KinomeScan一组402种激酶进行结合试验，其中80%为典型的人类蛋白激酶。测定所有激酶的解离常数。计算绝对选择性和作用于FLT的相对选择性。
细胞实验：^[1]	- 合并 Cell lines: MV4-11和RS4;11细胞 Concentrations: 0-100 nM Incubation Time: 72小时，及2小时 Method: 在增殖实验中，细胞培养在低血清培养基(含0.5% FBS)中过夜, 然后按每孔4×10⁴个细胞接种在96孔板上，然后加入AC220，37^oC下温育72小时。测定细胞活力。测定抑制FLT3自磷酸化的效果, 细胞培养在低血清培养基(含0.5% FBS)过夜，然后按每孔4×10⁵个细胞接种在96孔板上。细胞和AC220一起在37^oC下温育2小时，诱导 RS4;11细胞中FLT3自磷酸化, 加入100 ng/mL FLT3配位体，持续15分钟。转移细胞溶解物到用FLT3抗体包被的96孔板上。然后加入作用于FLT3的生物素化抗体，测定全部FLT3，或者作用于磷酸酪氨酸的抗体，测定FLT3自磷酸化。使用 SULFO标记的链霉亲和素二抗进行电化学发光测定。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 雌性裸鼠或严重联合免疫缺陷鼠 Dosages: 10 mL/kg Administration: 口服饲喂处理 (Only for Reference)

参考文献

[1] Zarrinkar PP, et al. Blood, 2009, 114(14), 2984-2992.

溶解度 (25°C)

体外	DMSO	33 mg/mL (58.85 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 15% Captisol	30 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Quizartinib (AC220) SDF

分子量	560.67
化学式	C₂₉H₃₂N₆O₄S
CAS号	950769-58-1
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2022-01-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04459598	Completed	Drug: Efavirenz\|Drug: Quizartinib	Healthy Subjects\|Drug-drug Interaction\|Pharmacokinetics\|Quizartinib	Daiichi Sankyo Co. Ltd.\|Daiichi Sankyo Inc.	September 8 2020	Early Phase 1
NCT04473664	Completed	Drug: Quizartinib	Hepatic Impairment\|Moderate Impaired Hepatic Function	Daiichi Sankyo Co. Ltd.\|Daiichi Sankyo Inc.	September 29 2020	Phase 1
NCT04459585	Completed	Drug: Dabigatran Etexilate Mesylate\|Drug: Quizartinib	Healthy Subjects\|Drug-drug Interaction\|Pharmacokinetics\|Quizartinib	Daiichi Sankyo Co. Ltd.\|Daiichi Sankyo Inc.	August 28 2020	Early Phase 1
NCT04209725	Terminated	Drug: CPX-351\|Drug: Quizartinib	Leukemia Myeloid Acute	SCRI Development Innovations LLC	June 3 2020	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
Is it possible to alter the captisol concentration to make it more dissolvable i.e 20% or 25% captisol ?
回答：
In 15% Captisol, the compound forms s suspension at 30mg/ml. Increasing the percentage of Captisol will not convert the mixture into solution. You can use suspension for oral gavage feeding.

Target Protein Ligand Inhibitors with Unique Features

用于临床的FLT3抑制剂

Dovitinib (TKI-258, CHIR-258) : Phase III for Metastatic Renal Cell Carcinoma.

研究领域

产品类型

定制您的化合物库

Quizartinib (AC220)

客户使用Selleck生产的Quizartinib (AC220)发表文献104篇：

产品安全说明书

Target Protein Ligand抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Quizartinib (AC220) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2022-01-17)

技术支持

常见问题及建议解决方法

Target Protein Ligand Inhibitors with Unique Features